Minimum antimicrobial treatment for acute pyelonephritis

摘要

Acute pyelonephritis is a common disease in healthy women. Genetic and behavioural factors, the most important of which is sexual intercourse, are, along with organism virulence, the determinants of infection.1 The clinical presentation is often serious; prompt, effective, empirical antimicrobial treatment is the cornerstone of management1 In The Lancet, Torsten Sandberg and colleagues2 report a clinical trial designed to confirm the non-inferiority of ciprofloxacin 500 mg twice a day for 7 days compared with the same regimen for 14 days, for treatment of women with acute pyelonephritis who were infected with ciprofloxacin-susceptible organisms.